A bio-assay for effectors of osteoclast differentiation in serum from patients with bone disease
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Dugard, Marit-NaomiSharp, Christopher A.
Evans, Sally F.
Williams, John H. H.
Davie, Michael W. J.
Marshall, Michael J.
Affiliation
Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; University of Chester ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in OswestryPublication Date
2005-06
Metadata
Show full item recordAbstract
Osteoclast differentiation and activity, and hence bone loss, depend on two opposing cytokines. Receptor activator of NF-κB ligand (RANKL) produced by osteoblasts and T-cells stimulates, while osteoprotegerin inhibits. Both of these cytokines are found in serum. Our aim was to develop a functional assay for any factors present in human serum that can affect osteoclast differentiation and to assess whether any such factors vary in diseases in which bone loss occurs.Citation
Clinica Chimica Acta, 356(1-2), (2005), pp. 154-163.Publisher
ElsevierJournal
Clinica Chimica ActaAdditional Links
http://www.elsevier.com/wps/find/journaldescription.cws_home/506018/description#descriptionType
ArticleLanguage
enDescription
This article is not available through ChesterRep.ISSN
0009-8981ae974a485f413a2113503eed53cd6c53
10.1016/j.cccn.2005.01.020